Mucopolysaccharidosis IIIB confers enhanced neonatal intracranial transduction by AAV8 but not by 5, 9 or rh10

Gene Therapy

Volumn 23, Issue 3, 2016, Pages 263-271

  Gilkes, J A ^a   Bloom, M D ^a   Heldermon, C D ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLGLUCOSAMINIDASE; GREEN FLUORESCENT PROTEIN;

ADENO ASSOCIATED VIRUS 8; ADENO ASSOCIATED VIRUS 9; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; BRAIN CORTEX; CEREBELLUM; CONTROLLED STUDY; GENE EXPRESSION; GENE TARGETING; GENE THERAPY; GENETIC TRANSDUCTION; GENOTYPE; HIPPOCAMPUS; MICROGLIA; MOUSE; MUCOPOLYSACCHARIDOSIS; MUCOPOLYSACCHARIDOSIS TYPE IIIB; NONHUMAN; OLIGODENDROGLIA; PRIORITY JOURNAL; RECOMBINANT ADENOASSOCIATED VIRUS; SEROTYPE; THALAMUS; TROPISM; ANIMAL; DEPENDOPARVOVIRUS; GENETICS; METABOLISM; MUCOPOLYSACCHARIDOSIS III; NEWBORN; PATHOPHYSIOLOGY; SKULL;

ANIMALS; ANIMALS, NEWBORN; DEPENDOVIRUS; GENETIC THERAPY; MICE; MUCOPOLYSACCHARIDOSIS III; SKULL; TRANSDUCTION, GENETIC;

EID: 84960115544     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2015.111     Document Type: Article

References (47)

1. Yogalingam G, Hopwood JJ. Molecular genetics of mucopolysaccharidosis type IIIA and IIIB: diagnostic, clinical and biological implications. Hum Mutat. 2001; 18: 264-281.
2. Gilkes J, Patterson B, Heldermon C, Mucopolysaccharidosis III. Molecular genetics and genotype-phenotype correlations. OA Genet. 2014; 2: 1.
3. Li HH, Yu W-H, Rozengurt N, Zhao H-Z, Lyons KM, Anagnostaras S, et al. Mouse model of Sanfilippo syndrome type B produced by targeted disruption of the gene encoding alpha-N-Acetylglucosaminidase. Proc Natl Acad Sci USA1999; 96: 14505-14510.
4. Heldermon CD, Hennig AK, Ohlemiller KK, Ogilvie JM, Herzog ED, Breidenbach, et al. Development of sensory, motor and behavioral deficits in the murine model of Sanfilippo Syndrome Type B. PLoS ONE. 2007; 2: e772.
5. Fu H, DiRosario J, Kang L, Muenzer J, McCarty DM. Restoration of central nervous system a-N-Acetylglucosaminidase activity and therapeutic benefits in mucopolysaccharidosis IIIB mice by a single intracisternal recombinant adeno-Associated viral type 2 vector delivery. J Gene Med. 2010; 12: 624-633.
6. Cressant A, Desmaris N, Verot L, Bréjot T, Froissart R, Vanier MT, et al. Improved behavior and neuropathology in the mouse model of Sanfilippo type IIIB disease after adeno-Associated virus-mediated gene transfer in the striatum. J Neurosci. 2004; 24: 10229-10239.
7. Ellinwood NM, Ausseil J, Desmaris N, Bigou S, Liu S, Jens JK, et al. Safe, efficient and reproducible gene therapy of the brain in the Dog models of Sanfilippo and Hurler syndromes. Mol Ther. 2011; 19: 251-259.
8. Liu G, Martins I, Wemmie JA, Chiorini JA, Davidson BL. Functional correction of CNS phenotypes in a lysosomal storage disease model using adeno-Associated virus type 4 vectors. J Neurosci. 2005; 25: 9321-9327.
9. Heuer GG, Passini MA, Jiang K, Parente MK, Lee VM-Y, Trojanowski JQ, et al. Selective neurodegeneration in murine mucopolysaccharidosis VII is progressive and reversible. Ann Neurol. 2002; 52: 762-770.
10. Passini MA, Wolfe JH. Widespread gene delivery and structure-specific patterns of expression in the brain after intraventricular injections of neonatal mice with an adeno-Associated virus vector. J Virol. 2001; 75: 12382-12392.
11. Passini MA, Watson DJ, Vite CH, Landsburg DJ, Feigenbaum AL, Wolfe JH. Intraventricular brain injection of adeno-Associated virus type 1 (AAV1) in neonatal mice results in complementary patterns of neuronal transduction to AAV2 and total long-Term correction of storage lesions in the brains of beta-glucuronidasedeficient mice. J Virol. 2003; 77: 7034-7040.
12. Sanchez CE, Tierney TS, Gale JT, Alavian KN, Sahin A, Lee J-S, et al. Recombinant adeno-Associated virus type 2 pseudotypes: comparing safety, specificity and transduction efficiency in the primate striatum. J Neurosurg. 2011; 114: 672-680.
13. Davidson BL, Stein CS, Heth JA, Martins I, Kotin RM, Derksen TA, et al. Recombinant adeno-Associated virus type 2, 4 and 5 vectors: transduction of variant cell types and regions in the mammalian central nervous system. Proc Natl Acad Sci USA. 2000; 97: 3428-3432.
14. Zincarelli C, Soltys S, Rengo G, Rabinowitz JE. Analysis of AAV serotypes 1-9 mediated gene expression and tropism in mice after systemic injection. Mol Ther. 2008; 16: 1073-1080.
15. Watson DJ, Passini MA, Wolfe JH. Transduction of the choroid plexus and ependyma in neonatal mouse brain by vesicular stomatitis virus glycoproteinpseudotyped lentivirus and adeno-Associated virus type 5 vectors. Hum Gene Ther. 2005; 16: 49-56.
16. Burger C, Gorbatyuk OS, Velardo MJ, Peden CS, Williams P, Zolotukhin S, et al. Recombinant AAV viral vectors pseudotyped with viral capsids from serotypes 1, 2 and 5 display differential efficiency and cell tropism after delivery to different regions of the central nervous system. Mol Ther. 2004; 10: 302-317.
17. Daly TM, Vogler C, Levy B, Haskins ME, Sands MS. Neonatal gene transfer leads to widespread correction of pathology in a murine model of lysosomal storage disease. Proc Natl Acad Sci USA. 1999; 96: 2296-2300.
18. Broekman MLD, Comer LA, Hyman BT, Sena-Esteves M. Adeno-Associated virus vectors serotyped with AAV8 capsid are more efficient than AAV-1 or -2 serotypes for widespread gene delivery to the neonatal mouse brain. Neuroscience. 2006; 138: 501-510.
19. Gliddon BL, Hopwood JJ. Enzyme-replacement therapy from birth delays the development of behavior and learning problems in mucopolysaccharidosis type IIIA mice. Pediatr Res. 2004; 56: 65-72.
20. Heldermon CD, Qin EY, Ohlemiller KK, Herzog ED, Brown JR, Vogler C, et al. Disease correction by combined neonatal intracranial AAV and systemic lentiviral gene therapy in Sanfilippo Syndrome type B mice. Gene Ther. 2013; 20: 913-921.
21. Gao G-P, Alvira MR, Wang L, Calcedo R, Johnston J, Wilson JM. Novel adenoassociated viruses from rhesus monkeys as vectors for human gene therapy. Proc Natl Acad Sci USA. 2002; 99: 11854-11859.
22. Gao G, Vandenberghe LH, Alvira MR, Lu Y, Calcedo R, Zhou X, et al. Clades of adeno-Associated viruses are widely disseminated in human tissues. J Virol. 2004; 78: 6381-6388.
23. Rabinowitz JE, Rolling F, Li C, Conrath H, Xiao W, Xiao X, et al. Cross-packaging of a single adeno-Associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J Virol. 2002; 76: 791-801.
24. Foust KD, Nurre E, Montgomery CL, Hernandez A, Chan CM, Kaspar BK. Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat Biotechnol. 2008; 27: 59-65.
25. Nonnenmacher M, Weber T. Intracellular transport of recombinant adenoassociated virus vectors. Gene Ther. 2012; 19: 649-658.
26. Zinn E, Vandenberghe LH. Adeno-Associated virus: fit to serve. Curr Opin Virol. 2014; 8C: 90-97.
27. Chen YH, Claflin K, Geoghegan JC, Davidson BL. Sialic acid deposition impairs the utility of AAV9, but not peptide-modified AAVs for brain gene therapy in a mouse model of lysosomal storage disease. Mol Ther. 2012; 20: 1393-1399.
28. Gray SJ, Nagabhushan Kalburgi S, McCown TJ, Jude Samulski R. Global CNS gene delivery and evasion of anti-AAV-neutralizing antibodies by intrathecal AAV administration in non-human primates. Gene Ther. 2013; 20: 450-459.
29. Cucchiarini M, Ren XL, Perides G, Terwilliger EF. Selective gene expression in brain microglia mediated via adeno-Associated virus type 2 and type 5 vectors. Gene Ther. 2003; 10: 657-667.
30. Cearley CN, Wolfe JH. Transduction characteristics of adeno-Associated virus vectors expressing cap serotypes 7, 8, 9 and Rh10 in the mouse brain. Mol Ther. 2006; 13: 528-537.
31. Schmidt M, Chiorini JA. Gangliosides are essential for bovine adeno-Associated virus entry. J Virol. 2006; 80: 5516-5522.
32. Sondhi D, Hackett NR, Peterson DA, Stratton J, Baad M, Travis KM, et al. Enhanced survival of the LINCL mouse following CLN2 gene transfer using the rh.10 Rhesus Macaque-derived adeno-Associated virus vector. Mol Ther. 2006; 15: 481-491.
33. Cachón-González MB, Wang SZ, Lynch A, Ziegler R, Cheng SH, Cox TM. Effective gene therapy in an authentic model of Tay-Sachs-related diseases. Proc Natl Acad Sci USA. 2006; 103: 10373-10378.
34. Haurigot V, Marcó S, Ribera A, Garcia M, Ruzo A, Villacampa P, et al. Whole body correction of mucopolysaccharidosis IIIA by intracerebrospinal fluid gene therapy. J Clin Invest. 2013; 123: 3254-3271.
35. Kumar KR, Djarmati-Westenberger A, Grünewald A. Genetics of Parkinsons disease. Semin Neurol. 2011; 31: 433-440.
36. Yamanaka K, Chun SJ, Boillee S, Fujimori-Tonou N, Yamashita H, Gutmann DH, et al. Astrocytes as determinants of disease progression in inherited amyotrophic lateral sclerosis. Nat Neurosci. 2008; 11: 251-253.
37. Zhang H, Yang B, Mu X, Ahmed SS, Su Q, He R, et al. Several rAAV vectors efficiently cross the blood-brain barrier and transduce neurons and astrocytes in the neonatal mouse central nervous system. Mol Ther. 2011; 19: 1440-1448.
38. Gray SJ, Matagne V, Bachaboina L, Yadav S, Ojeda SR, Samulski RJ. Preclinical differences of intravascular AAV9 delivery to neurons and glia: a comparative study of adult mice and nonhuman primates. Mol Ther. 2011; 19: 1058-1069.
39. Yang B, Li S, Wang H, Guo Y, Gessler DJ, Cao C, et al. Global CNS transduction of adult mice by intravenously delivered rAAVrh.8 and rAAVrh.10 and nonhuman primates by rAAVrh.10. Mol Ther. 2014; 22: 1299-1309.
40. Ribera A, Haurigot V, Garcia M, Marcó S, Motas S, Villacampa P, et al. Biochemical, histological and functional correction of mucopolysaccharidosis Type IIIB by intracerebrospinal fluid gene therapy. Hum Mol Genet. 2015; 24: 2078-2095.
41. Petrs-Silva H, Dinculescu A, Li Q, Min S-H, Chiodo V, Pang J-J, et al. High-efficiency transduction of the mouse retina by tyrosine-mutant AAV serotype vectors. Mol Ther. 2009; 17: 463-471.
42. Gabriel N, Hareendran S, Sen D, Gadkari RA, Sudha G, Selot R, et al. Bioengineering of AAV2 capsid at specific serine, threonine, or lysine residues improves its transduction efficiency in vitro and in vivo. Hum Gene Ther Methods. 2013; 24: 80-93.
43. Sen D, Gadkari RA, Sudha G, Gabriel N, Kumar YS, Selot R, et al. Targeted modifications in adeno-Associated virus serotype 8 capsid improves its hepatic gene transfer efficiency in vivo. Hum Gene Ther Methods. 2013; 24: 104-116.
44. Martini SV, da Silva AL, Ferreira D, Gomes K, Ornellas FM, Lopes-Pacheco M, et al. Single tyrosine mutation in AAV8 vector capsid enhances gene lung delivery and does not alter lung morphofunction in mice. Cell Physiol Biochem. 2014; 34: 681-690.
45. Zolotukhin S, Potter M, Zolotukhin I, Sakai Y, Loiler S, Fraites TJ Jr, et al. Production and purification of serotype 1, 2 and 5 recombinant adeno-Associated viral vectors. Methods. 2002; 28: 158-167.
46. Marsh J, Fensom AH. 4-Methylumbelliferyl alpha-N-Acetylglucosaminidase activity for diagnosis of Sanfilippo B disease. Clin Genet. 1985; 27: 258-262.
47. Heldermon CD, Ohlemiller KK, Herzog ED, Vogler C, Qin E, Wozniak DF, et al. Therapeutic efficacy of bone marrow transplant, intracranial AAV-mediated gene therapy, or both in the mouse model of MPS IIIB. Mol Ther. 2010; 18: 873-880.